The companies aim to develop and commercialize SER-252 (POZ-apomorphine) in combination with enFuse to treat Parkinson’s disease. This deal builds upon a recent agreement that allows Roche to obtain a worldwide, exclusive license to develop and commercialize combinations of enFuse with specific molecules.
Under the terms of the agreement, Serina will obtain a worldwide, exclusive license to the enFuse platform for an upfront and future milestone payments. Enable will also be entitled to product sales and single digit royalties.
Enable Injections designed enFuse, a mechanical, wearable drug delivery device, to deliver large volumes of small molecule and biologic medications subcutaneously. Patients can receive their needed treatment in a single injection under the skin, rather than the intravenous route.
The FDA cleared enFuse for the delivery of Empaveli in October 2023. The company says it’s the first-ever hands-free wearable technology that allows patients to self-administer large-volume medications subcutaneously without an IV or syringe pump.
SER-252, an investigational therapy, was designed to deliver continuous dopaminergic stimulation (CDS). This can reduce the severity of levodopa-related motor complications (dyskinesia) in Parkinson’s disease. Serina plans to advance the therapy to clinical testing in 2025.
Dr. Randall Moreadith, Serina’s chief development officer, says the collaboration enables self-administration in the patient’s own home. Additionally, Moreadith said the wearable technology can provide a rapid treatment time and keep patients in continuous “on” state.
“The partnership with Serina Therapeutics continues to validate the applicability of enFuse across various therapeutic areas, even in the field of Parkinson’s, where multiple routes of treatment administration already exist, including subcutaneous methods. The technology and benefits of enFuse have the potential to significantly reduce many of the burdens associated with the current standard of care for Parkinson’s,” said Mike Hooven, chair and CEO of Enable Injections. “We greatly look forward to bringing those living with, and treating, Parkinson’s disease an improved treatment experience that is more convenient, less time-consuming, and less disruptive to their lives with SER-252 in combination with enFuse.”
